<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342351</url>
  </required_header>
  <id_info>
    <org_study_id>CRP</org_study_id>
    <nct_id>NCT04342351</nct_id>
  </id_info>
  <brief_title>Early Treatment of ARNI on Myocardial Remodeling and Progress</brief_title>
  <official_title>Early Treatment of ARNI on Myocardial Remodeling and Progress in Patients With Post-AMI (EARLYmyo-CRPⅠ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial remodeling following myocardial infarction (MI) is an important prognostic factor
      for heart function and adverse cardiovascular events, especially are intimately linked with
      heart failure. MI often causes deleterious changes in ventricular size, shape, and function.
      This adverse remodeling and progress is mediated by neurohormonal and hemodynamic
      alterations. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
      shown to be superior to an ACE inhibitor in patients with heart failure with reduced ejection
      fraction (HF-REF), reduce the risk of both death (from cardiovascular and all-causes) and
      heart failure hospitalization, may be a new approach to the treatment of heart failure.
      However, the impact of early treatment of ARNI on myocardial remodeling and progress, and
      aerobic exercise capacity in patients with prior MI has yet to be assessed. The aim of this
      study is to evaluate the efficacy and the safety of early treatment of ARNI on myocardial
      remodeling and progress, and aerobic exercise capacity in patients following MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myocardial remodeling following myocardial infarction (MI) is an important prognostic factor
      for heart function and adverse cardiovascular events. The angiotensin receptor neprilysin
      inhibitor (ARNI) sacubitril/valsartan was shown to reduce the risk of both death (from
      cardiovascular and all-causes) and heart failure hospitalization. However, whether early
      treatment of ARNI following post-MI could alter myocardial remodeling or aerobic exercise
      capacity has yet to be assessed. The patients with MI within one month were enrolled in the
      treatment of ARNI group or ACEI group. The study proposes to perform serial Cardiopulmonary
      Exercise Tests (CPET) to prospectively measure changes in aerobic exercise capacity in
      patients with prior myocardial infarction (MI), echocardiographic measures of LV
      end-diastolic/ systolic volumes, LV ejection fraction (LVEF), BNP and protein plasma levels,
      symptomatic heart failure, and life quality.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen consumption (VO2)/kg</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in the interval change from baseline in peak VO2/kg at 3 months following sacubitril/valsartan from 25mg/b.i.d, 50mg b.i.d, to target dosage 100mg b.i.d for 3 months, when compared with the interval change in perindopril from 2mg q.d, 4mg q.d, to target dosage 8mg q.d for 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Oxygen Pulse (O2-Pulse)</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in the interval change from baseline in peak O2-Pulse at 3 months following sacubitril/valsartan or perindopril.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LVEF</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in the interval changes from baseline in left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV) by echocardiography assessment at 3 months, comparing sacubitril/valsartan with perindopril.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak VO2/kg change</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in the interval changes from baseline and 6 months in peak VO2 comparing sacubitril/valsartan with perindopril.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Oxygen Pulse change</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in the interval changes from baseline and 6 months in peak O2-Pulse comparing sacubitril/valsartan with perindopril.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory efficiency (VE/VCO2 slope) change</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in the interval changes from baseline and 6 months in the VE/VCO2 slope comparing sacubitril/valsartan with perindopril.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF change</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in the interval changes from baseline in LVEF, LVESV, and left LVEDV at 6 months, comparing sacubitril/valsartan with perindopril.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) change</measure>
    <time_frame>Baseline, 3, 6 months</time_frame>
    <description>Change in concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to 3 months , 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The MOS item short form health survey, SF-36</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study. The SF-36 was designed for use in clinical practice and research, health policy evaluations, and general population surveys. The SF-36 includes one multi-item scale that assesses eight health concepts. The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Experimental: sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sacubitril/valsartan will be applied from 25mg b.i.d to 100mg b.i.d. for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: perindopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>perindopril will be applied from 2mg q.d, to 8mg q.d for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan</intervention_name>
    <description>sacubitril/valsartan will be applied from 25mg/b.i.d for 1-2 weeks,50mg b.i.d for 2 weeks, to target dosage 100mg b.i.d for 3 months unless severe safety outcome occurs</description>
    <arm_group_label>Experimental: sacubitril/valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perindopril</intervention_name>
    <description>Drug: perindopril will be applied from 2mg for q.d for 1-2 weeks, 4mg q.d 2 weeks, to target dosage 8mg q.d for 3 months unless severe safety outcome occur</description>
    <arm_group_label>Active Comparator: perindopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary Exercise Test</intervention_name>
    <description>All patients will undergo a first CPET prior to initiation of treatment, a second one after 3 months, and a third one after 6 months of treatment.</description>
    <arm_group_label>Active Comparator: perindopril</arm_group_label>
    <arm_group_label>Experimental: sacubitril/valsartan</arm_group_label>
    <other_name>CPET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 3 months, 6 months later.</description>
    <arm_group_label>Active Comparator: perindopril</arm_group_label>
    <arm_group_label>Experimental: sacubitril/valsartan</arm_group_label>
    <other_name>ECHO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute myocardial infarction (AMI) within 1 months prior to recruitment;

          2. Aged 18 years or over and under 80 years;

          3. Randomized patients will have been hemodynamically stable, SBP ≥100mmHg, no
             symptomatic hypotension;

          4. NYHA Class Ⅱ-Ⅳ, HFrEF or HFpEF;

          5. Elevated NT-proBNP or BNP at the time of screening;

          6. Peak VO2/kg&lt;16 ml/kg/min by CPET

        Exclusion Criteria:

          1. Inability to complete a CPET;

          2. Symptomatic hypotension and/or systolic blood pressure &lt;100mmHg;

          3. eGFR &lt; 30 mL/min/1.73m2 and/or serum potassium &gt;5.2mmol/L;

          4. History of hypersensitivity or allergy to ACE-inhibitors/ARB

          5. History of angioedema;

          6. Pregnancy, planning pregnancy, or breast feeding;

          7. Life-threatening diseases with limited life expectancy &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qin Shao, M.D,Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Ma, M.D,Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qin Shao, M.D,Ph.D</last_name>
    <phone>86-21-68385225</phone>
    <email>shaoqindr@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Ma, M.D,Ph.D</last_name>
    <phone>86-21-68383164</phone>
    <email>drjunma@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RenJi Hospital, Shanghai JiaoTong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qin Shao, M.D,Ph.D</last_name>
      <phone>86-21-68385225</phone>
      <email>shaoqindr@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Ma, M.D,Ph.D</last_name>
      <phone>86-21-68383164</phone>
      <email>drjunma@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

